Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Lung Cancer 1Solid Tumors 1Breast Neoplasms 1

Interventions

Paclitaxel 23Carboplatin 22Capecitabine 18Gemcitabine 16130-nm albumin-bound paclitaxel 16pembrolizumab 14Cyclophosphamide 12atezolizumab 9Epirubicin 9sacituzumab govitecan 8Albumin-Bound Paclitaxel 8eribulin 6Vinorelbine 6Drug Therapy 6Doxorubicin 6camrelizumab 4Docetaxel 4Cisplatin 4Injections 3pegfilgrastim 2olaparib 2famitinib 2Filgrastim 2Everolimus 2veliparib 1trilaciclib 1toripalimab 1taxane 1niraparib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Triple Negative Breast Neoplasms × iniparib × Clear all
NCT00938652 2013-09-19

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Sanofi

Phase 3 Completed
519 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡